Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT SOUTH SAN FRANCISCO, Calif. , Jan. 16, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced that it will host a conference call